Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression
- PMID: 35138511
- DOI: 10.1007/s11010-022-04377-5
Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression
Erratum in
-
Correction to: Novel role of the Mu‑opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression.Mol Cell Biochem. 2022 May;477(5):1347. doi: 10.1007/s11010-022-04400-9. Mol Cell Biochem. 2022. PMID: 35212863 No abstract available.
Abstract
Opioids are the most popular drugs for both acute and chronic pain management. The G protein-coupled mu-opioid receptor (MOR) is the therapeutic target for most clinically used opioids, including morphine. A mounting number of publications suggest a relationship between the MOR and possible cancer progression and recurrence extending to managing chronic cancer pain. In this study, we studied the possible link between opioid use and pancreatic cancer (PC) progression. We found increased MOR expression in murine and human PC cell lines, human PC-derived organoids, and in the undifferentiated or poorly differentiated areas of surgically resected PC tissues. Direct stimulation of MOR by morphine (MOR agonist) caused a significant dose-dependent increase in proliferation, invasion, and levels of stemness markers in PC cells. In a co-culture system, MOR stimulation of macrophages also resulted in increased proliferation of PC cells. MOR overexpression increased proliferation and cancer stemness, whereas knock-down of MOR followed opposite results in the PC cells. Morphine induced chemoresistance to conventional chemotherapeutic agents used for PC treatment. Overall, our results suggest that MOR is expressed in pancreatic cancer and may be involved in tumor progression and chemoresistance.
Keywords: MOR; Morphine; Opioid; Pancreatic cancer.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Similar articles
-
Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.PLoS One. 2015 Aug 13;10(8):e0135711. doi: 10.1371/journal.pone.0135711. eCollection 2015. PLoS One. 2015. PMID: 26270813 Free PMC article.
-
Antinociceptive effects of morphine and naloxone in mu-opioid receptor knockout mice transfected with the MORS196A gene.J Biomed Sci. 2010 Apr 20;17(1):28. doi: 10.1186/1423-0127-17-28. J Biomed Sci. 2010. PMID: 20403204 Free PMC article.
-
Regulation of mammalian MOR-1 gene expression after chronic treatment with morphine.Int J Mol Med. 2012 Dec;30(6):1493-7. doi: 10.3892/ijmm.2012.1132. Epub 2012 Sep 19. Int J Mol Med. 2012. PMID: 22992838 Free PMC article.
-
The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.Channels (Austin). 2015;9(5):235-43. doi: 10.1080/19336950.2015.1069450. Epub 2015 Jul 15. Channels (Austin). 2015. PMID: 26176938 Free PMC article. Review.
-
Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance.Curr Drug Abuse Rev. 2012 Sep;5(3):199-226. doi: 10.2174/1874473711205030199. Curr Drug Abuse Rev. 2012. PMID: 22920535 Review.
Cited by
-
Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma.J Immunother Cancer. 2024 Nov 17;12(11):e009962. doi: 10.1136/jitc-2024-009962. J Immunother Cancer. 2024. PMID: 39551606 Free PMC article.
-
Opioids and Cancer: Current Understanding and Clinical Considerations.Curr Oncol. 2024 May 30;31(6):3086-3098. doi: 10.3390/curroncol31060235. Curr Oncol. 2024. PMID: 38920719 Free PMC article. Review.
-
Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals the Immunotherapeutic Value of Toll-Like Receptor 4.Int J Gen Med. 2023 Nov 24;16:5527-5548. doi: 10.2147/IJGM.S434076. eCollection 2023. Int J Gen Med. 2023. PMID: 38034898 Free PMC article.
-
Reducing Postoperative Opioid Use: A Comparison of Open Versus Ultrasound-Guided Regional Anesthesia for Patients Undergoing Open Pancreatoduodenectomy.J Surg Oncol. 2025 Jun;131(7):1343-1351. doi: 10.1002/jso.28074. Epub 2025 Jan 8. J Surg Oncol. 2025. PMID: 39780451
-
Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids.J Tissue Eng. 2024 May 27;15:20417314241255470. doi: 10.1177/20417314241255470. eCollection 2024 Jan-Dec. J Tissue Eng. 2024. PMID: 38808253 Free PMC article. Review.
References
-
- Adamska A, Domenichini A, Falasca M (2017) Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. https://doi.org/10.3390/ijms18071338 - DOI - PubMed - PMC
-
- Sheikh M, Shakeri R, Poustchi H, Pourshams A, Etemadi A, Islami F, Khoshnia M, Gharavi A, Roshandel G, Khademi H, Sepanlou SG, Hashemian M, Fazel A, Zahedi M, Abedi-Ardekani B, Boffetta P, Dawsey SM, Pharoah PD, Sotoudeh M, Freedman ND, Abnet CC, Day NE, Brennan P, Kamangar F, Malekzadeh R (2020) Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. Lancet Glob Health 8:e649–e660. https://doi.org/10.1016/S2214-109X(20)30059-0 - DOI - PubMed - PMC
-
- Kamangar F, Shakeri R, Malekzadeh R, Islami F (2014) Opium use: an emerging risk factor for cancer? Lancet Oncol 15:e69-77. https://doi.org/10.1016/S1470-2045(13)70550-3 - DOI - PubMed
-
- Moossavi S, Mohamadnejad M, Pourshams A, Poustchi H, Islami F, Sharafkhah M, Mirminachi B, Nasseri-Moghaddam S, Semnani S, Shakeri R, Etemadi A, Merat S, Khoshnia M, Dawsey SM, Pharoah PD, Brennan P, Abnet CC, Boffetta P, Kamangar F, Malekzadeh R (2018) Opium use and risk of pancreatic cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 27:268–273. https://doi.org/10.1158/1055-9965.EPI-17-0592 - DOI - PubMed
-
- Barlass U, Deshmukh A, Beck T, Bishehsari F (2021) Opioid use as a potential risk factor for pancreatic cancer in the United States: an analysis of state and national level databases. PLoS ONE 16:e0244285. https://doi.org/10.1371/journal.pone.0244285 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials